Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function

OBJECTIVE To determine the association between laboratory-derived measures of glycemic control (HbA1c) and the presence of renal complications (measured by proteinuria and estimated glomerular filtration rate [eGFR]) with the 5-year costs of caring for people with diabetes. RESEARCH DESIGN AND METHODS We estimated the cumulative 5-year cost of caring for people with diabetes using a province-wide cohort of adults with diabetes as of 1 May 2004. Costs included physician visits, hospitalizations, ambulatory care (emergency room visits, day surgery, and day medicine), and drug costs for people >65 years of age. Using linked laboratory and administrative clinical and costing data, we determined the association between baseline glycemic control (HbA1c), proteinuria, and kidney function (eGFR) and 5-year costs, controlling for age, socioeconomic status, duration of diabetes, and comorbid illness. RESULTS We identified 138,662 adults with diabetes. The mean 5-year cost of diabetes in the overall cohort was $26,978 per patient, excluding drug costs. The mean 5-year cost for the subset of people >65 years of age, including drug costs, was $44,511 (Canadian dollars). Cost increased with worsening kidney function, presence of proteinuria, and suboptimal glycemic control (HbA1c >7.9%). Increasing age, Aboriginal status, socioeconomic status, duration of diabetes, and comorbid illness were also associated with increasing cost. CONCLUSIONS The cost of caring for people with diabetes is substantial and is associated with suboptimal glycemic control, abnormal kidney function, and proteinuria. Future studies should assess if improvements in the management of diabetes, assessed with laboratory-derived measurements, result in cost reductions.

[1]  Philip Jacobs,et al.  The cost of major comorbidity in people with diabetes mellitus. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  T. Gilmer,et al.  Predictors of health care costs in adults with diabetes. , 2005, Diabetes care.

[3]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[4]  J. Caro,et al.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.

[5]  R. Rosenson,et al.  Does microvascular disease predict macrovascular events in type 2 diabetes? , 2011, Atherosclerosis.

[6]  S. Pohar,et al.  Health care utilization and costs in Saskatchewan's registered Indian population with diabetes , 2007, BMC Health Services Research.

[7]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[8]  Jonathan C Craig,et al.  Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. , 2006, Journal of the American Society of Nephrology : JASN.

[9]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[10]  E. Bonora,et al.  Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[11]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[12]  W. Manning,et al.  The Cost to Health Plans of Poor Glycemic Control , 1997, Diabetes Care.

[13]  M. Woodward,et al.  Lowering blood pressure reduces renal events in type 2 diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[14]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[15]  R. Stolk,et al.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. , 2004, The Cochrane database of systematic reviews.

[16]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[18]  C. Lawton Highlights of the 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. , 2004, CANNT journal = Journal ACITN.

[19]  A. Wajda,et al.  Incidence and Prevalence of Diabetes in Manitoba, 1986–1991 , 1996, Diabetes Care.

[20]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[21]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[23]  B. Kasiske,et al.  Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis , 1993, Annals of Internal Medicine.

[24]  J. Caro,et al.  Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus , 2012, PharmacoEconomics.

[25]  B. Wells,et al.  Health Care and Productivity Costs Associated With Diabetic Patients With Macrovascular Comorbid Conditions , 2009, Diabetes Care.

[26]  Janet E Hux,et al.  Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study , 2007, The Lancet.

[27]  Morton B. Brown,et al.  The direct medical cost of type 2 diabetes. , 2003, Diabetes care.

[28]  C. Truman,et al.  Influence of aboriginal and socioeconomic status on birth outcome and maternal morbidity. , 2002, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[29]  M. Aagren,et al.  Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States , 2011, Journal of medical economics.

[30]  N. Duan Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[31]  E H Wagner,et al.  Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.

[32]  Chris Cameron,et al.  Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis , 2011, Open medicine : a peer-reviewed, independent, open-access journal.

[33]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[34]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[35]  K. Secnik,et al.  The association between diabetes related medical costs and glycemic control: A retrospective analysis , 2006, Cost effectiveness and resource allocation : C/E.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[39]  J. Stoker,et al.  The Department of Health and Human Services. , 1999, Home healthcare nurse.

[40]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[41]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[42]  Jennifer MacRae,et al.  Overview of the Alberta Kidney Disease Network , 2009, BMC nephrology.

[43]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.